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In general, autoimmune diseases com-
prise a group of diseases of unknown
etiology in which it is thought that by
some unknown mechanism the pa-
tient’s own immune system fails to
recognize ‘‘self’’ cells or proteins and
mounts an immune response against
one or more of the host’s own tissues.
In many putative autoimmune diseases
such as systemic lupus erythematosus,
dermatomyositis, scleroderma, mixed
connective tissue disease, and rheuma-
toid arthritis, the autoantibodies and
their autoantigenic targets have not
been well defined. This has made it
difficult to prove in animal models that
the autoantibodies binding to their
respective target proteins or cells in
the host are responsible for the disease.
In contrast, investigative dermatology
has been fortunate to define and
characterize the autoantibodies and
autoantigenic targets in a number of
autoimmune bullous diseases of the
skin, including pemphigus vulgaris (PV),
pemphigus foliaceous, cicatricial pem-
phigoid (CP), epidermolysis bullosa
acquisita (EBA), and bullous pemphi-
goid (BP). In the domain of infectious
diseases, it has been said that the proof
that an infectious agent causes a
disease lies in inoculating an animal
with the infectious agent and duplicat-
ing the disease: so-called Koch’s pos-
tulate. In the realm of autoimmunity,
the ultimate proof that autoantibodies
are pathogenic and responsible for an
autoimmune disease lies in injecting
the autoantibody into an animal (usual-
ly a mouse) and creating the disease in
that animal. This has been termed a
‘‘passive transfer’’ experiment; it defi-
nitively proves that the autoantibody is
‘‘pathogenic’’ and causes the disease.
For dermatological diseases, the
passive transfer of an autoimmune
disease was first accomplished by
Anhalt et al. (1982) who took IgG
autoantibodies from the sera of patients
with PV, injected them into newborn
mice and created a pemphigus-like
disease in the mice that included
acantholytic intraepidermal bullae and
animals with positive direct and indir-
ect immunofluorescence findings akin
to human patients with PV. We now
know that the human IgG autoantibo-
dies passively transferred into these
mice contained antibodies against des-
moglein 3 (Dsg3), a major component
of the desmosomal junctions that hold
keratinocytes together in the epidermis.
The human PV anti-Dsg3 autoantibo-
dies bound to the Dsg3 in mouse skin
and induced acantholysis and blister
formation. Later, a similar set of experi-
ments by Rock et al. (1989) demon-
strated that one could also create
pemphigus foliaceous in a mouse by
passively transferring IgG4 antibodies
against desmoglein 1 from patients with
endemic pemphigus foliaceous and very
precisely create pemphigus foliaceous
in the animal, with acantholytic bullae
developing high in the epidermis.
In addition to the pemphigus passive
transfer murine models, Amagai et al.,
2000 also established an ‘‘active’’
murine model of pemphigus. This was
a creative and elegant experimental
strategy, in which they injected Dsg3
null knockout mice with exogenous
Dsg3, and the mice generated anti-
Dsg3 antibodies. The authors then took
the splenic lymphocytes from these
mice and transplanted them into im-
munodeficient mice that natively ex-
pressed Dsg3 in the epidermal
desmosomes of their skin. These trans-
planted mice then generated anti-Dsg3
antibodies for many months, and these
‘‘autoantibodies’’ bound to the murine
Dsg3 in their skin and created intrae-
pidermal acantholytic bullae. There-
fore, these mice, just like patients with
PV, had intercellular cement substance
pemphigus-like indirect immunofluor-
escence, direct immunofluorescence,
and intraepidermal acantholytic blisters
on their skin and in their oral mucosa
(Amagai et al., 2000).
One might assume that all autoim-
mune antibodies would likely be
‘‘pathogenic’’ and induce the blistering
disease. This is not the case. Many
autoantibodies are only associated with
the disease and ‘‘mark’’ the disease, but
do not cause a disease phenotype such
as skin blisters. One example of this is
pemphigus paraneoplastica, first iden-
tified and characterized by Anhalt et al.
(1990). These patients have an
acantholytic intraepidermal blistering
disorder similar to pemphigus in asso-
ciation with an underlying malignancy.
In the patient’s serum one finds high-
titer antibodies to the ‘‘plakin proteins’’
such as desmoplakin I, desmoplakin II,
the 230 kDa BP antigen 1, envoplakin,
and periplakin. These patients also
have IgG autoantibodies to Dsg3, just
like PV patients. It was shown by
Amagai et al. (1998) that it is the IgG
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autoantibodies to Dsg3 that actually
cause the bullous lesions in these
patients whereas the antibodies to the
plakin proteins are nonpathogenic and
only markers of the disease. By indirect
immunofluorescence staining, the anti-
plakin antibodies in pemphigus para-
neoplastica patients label rodent sub-
strates that are rich in plakin proteins
such as mouse bladder and mouse
heart, whereas sera from PV patients
do not. Therefore, the pathogenic anti-
bodies to Dsg3 are the same in both PV
and pemphigus paraneoplastica pa-
tients, whereas the latter disease has
many anti-plakin ‘‘marker’’ autoantibo-
dies that are not involved with the
phenotype of the disease, but are useful
to the clinician for diagnosing it.
In terms of subepidermal autoim-
mune bullous diseases, both EBA and
anti-epiligrin (aka anti-laminin-5) CP
have been passively transferred into
animals (Lazarova et al., 1996, 2000;
Sitaru et al., 2005; Woodley et al.,
2005, 2006; Chen et al., 2007). IgG
fractions of sera from patients with EBA
were injected into hairless mice, and
the mice developed subepidermal blis-
ters, human IgG deposits at the derma-
l–epidermal junction, and nail loss—all
features of human EBA (Woodley et al.,
2006). In further experiments, affinity-
purified IgG antibodies against a small,
20 kDa, subdomain of the amino
terminus of type VII (anchoring
fibril) collagen from EBA patient sera,
were injected into mice, causing
them to develop blisters and nail
loss as they did in experiments with
whole EBA patient sera, showing
that EBA patient antibodies against a
small domain of the autoantigenic
target (Mr¼ 290,000 Da) could be
highly pathogenic (Chen et al., 2007).
In concordance with these studies of
human EBA patient sera, rabbits can be
immunized against mouse or human
type VII collagen (C-7) and high-titer
anti-C-7 antibodies generated. When
these rabbit IgG C-7 antibodies are
injected into mice, the mice develop an
EBA-like disease (Sitaru et al., 2005;
Woodley et al., 2005). In all of these
murine EBA models, the blister pheno-
type appears to depend upon the
fixation of complement. More recently,
Sitaru et al. (2006) in the Zillikens
laboratory developed an active EBA
model, which appears to be highly
dependent upon the genetics of the
strain of mouse used. They injected
murine C-7 into several strains of mice
and certain strains, such as SJL-1 mice,
were highly susceptible to developing
anti-C-7 antibodies and an EBA-like
disease, whereas EBA could not be
induced in SKH-1 mice. This murine
work is interesting in light of the
observations of Gammon et al. (1988)
that certain human HLA types such as
HLA DR2 predispose individuals to
develop EBA.
Patients who have CP, a mucosal-
centered, subepidermal, bullous disor-
der, have been described with IgG
autoantibodies against a number of
dermal–epidermal junction proteins in
the skin including collagen types VII
and XVII, laminin-5 (aka: ‘‘epiligrin’’,
‘‘kalanin’’, ‘‘nicein’’, ‘‘BM 600’’), the
230 kDa BP antigen 1, and other less
well-defined proteins. Nevertheless,
one subset of CP patients that has been
well defined is those with anti-laminin-
5 CP. These elderly patients have IgG
autoantibodies against an anchoring
filament protein within the lamina
lucida called laminin-5 and a host of
other previous names (vide supra). This
is a cruciate glycoprotein consisting of
a central a-3 chain flanked by b-3 and
g-2 chains. Most anti-laminin-5 pa-
tients have autoantibodies to the cen-
tral a-chain. Lazarova et al. (1996,
2000) injected anti-laminin-5 IgG anti-
bodies into mice, causing them to
develop subepidermal bullae and ero-
sions of their skin and mucous mem-
branes. Noncomplement fixing IgG4
antibodies and the Fab fragment of
anti-laminin-5 can both passively trans-
fer the disease in mice, demonstrating
that complement is not required for the
generation of murine anti-laminin-5 CP
(Lazarova et al., 2000). Although anti-
laminin-5 antibodies can clearly in-
duce one of the main features of the
disease, namely subepidermal bullae
and erosions, it is not clear why the
murine disease is not scarring and
mucosal-limited like human CP.
Hall et al. (1993) were unable to
passively transfer BP into mice by
injecting antibodies against a domain
of the 230 kDa BP antigen 1 unless the
mice were subjected to an inflamma-
tory stimulus first, such as UV light
irradiation. It was thought that the skin
first needed to be perturbed such that
the basal keratinocyte plasma mem-
brane was compromised and subse-
quently exposed the BP antigen 1
within the hemidesmosome. In contrast
to these studies with the 230 kDa BP
antigen 1, Liu et al. (1993) showed that
the amino-acid sequence of the auto-
antibody-binding domain, so-called
NC16A, of the 180 kDa BP antigen 2
(type XVII collagen) was different be-
tween the human and murine forms of
type XVII collagen. Therefore, one
would not expect human BP sera to
have anti-type XVII antibodies that
could bind to the mouse NC16A
pathogenic epitope and invoke BP in
mice. To overcome this problem, Liu
immunized rabbits with the murine
corollary of the antibody-binding site
on the human molecule, and by inject-
ing these anti-mouse type XVII collagen
rabbit antibodies into mice was able to
consistently generate a BP-like disease.
In further studies, Liu et al. (1995,
2000a, b) showed that the induction of
murine BP required complement, re-
quired neutrophils, and was mediated
through neutrophil elastase. In a more
recent study, Nishie et al. (2007)
generated transgenic mice expressing
the human BP 180. Using this mouse
model, they injected human BP auto-
antibody into these mice and induced
BP-like skin lesions reminiscent of hu-
man BP.
Although the murine form of BP was
similar to human BP in many ways, it
lacked some hallmarks of the human
disease such as the lack of inflamma-
tion, edema, and eosinophils which are
almost always noted in human BP.
Recently, Fairley et al. (2005, 2007)
observed that human BP patients often
have IgE autoantibodies that label both
the dermal–epidermal junction of hu-
man skin as well as dermal mast cells
that are almost always seen in the high
papillary dermis of BP patients. These
BP IgE autoantibodies bind to the same
epitopes of type XVII collagen as BP
IgG autoantibodies (Fairley et al.,
2005). In addition, these IgE autoanti-
bodies on the mast cells become cross-
linked and dimerized by the presence
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of dermal ‘‘bridging’’ fragments of type
XVII collagen, which then induce mast
cell degranulation and the recruitment
of eosinophils into the area. Using
human skin grafted onto mice, the
injection of BP IgE autoantibodies
invoked the attraction of eosinophils
into the skin with subsequent erythe-
ma, urticaria, and edema. In the case of
BP, therefore, it appears that both IgG
and IgE autoantibodies directed against
type XVII collagen are ‘‘pathogenic’’
and responsible for different aspects of
the disease phenotype.
In summary, animal models of auto-
immune bullous diseases have clearly
shown that there are ‘‘marker’’ anti-
bodies that herald the disease and
‘‘pathogenic’’ antibodies that cause
the disease. They have shown that
various subdomains on the target auto-
antigen can generate highly pathogenic
autoantibodies whereas other subdo-
mains cannot. These models have also
been useful for determining the me-
chanisms and parameters of the disease
pathogenesis such as the role of com-
plement, the role of various inflamma-
tory cells, and the role of specific
proteinases. These advances in our
understanding of these diseases will
help clinician scientists in the future
tailor treatment strategies based on the
mechanistic parameters of each dis-
ease.
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